CIK 0001841330 · <br>Emerging growth company
Pasithea Therapeutics Corp.
Sign in to watch- Ticker
- KTTA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851591963
- Phone
- (702) 514-4174
- Business address
- 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL, 33139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-13 | Novak Alfred J Director | Grant or award | +2,750 | $5.62 | $15K | 3,500 |
| 2024-06-12 | Novak Alfred J Director | Grant or award | +750 | $5.61 | $4K | 750 |
| 2024-03-01 | Marques Tiago Chief Executive Officer | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2024-03-01 | Marques Tiago Chief Executive Officer | Grant or award · Stock Option (right to buy) | +11,669 | 11,669 | ||
| 2024-03-01 | Leahy Emer Director | Grant or award · Stock Option (right to buy) | +7,500 | 7,500 | ||
| 2024-03-01 | Schneiderman Daniel H Chief Financial Officer | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-03-01 | Schneiderman Daniel H Chief Financial Officer | Grant or award · Stock Option (right to buy) | +5,927 | 5,927 | ||
| 2024-03-01 | Novak Alfred J Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2024-03-01 | Currie Graeme Martin Chief Development Officer | Grant or award · Stock Option (right to buy) | +5,938 | 5,938 | ||
| 2024-03-01 | Dumesnil Simon Director | Grant or award · Stock Option (right to buy) | +7,500 | 7,500 | ||
| 2024-03-01 | STEINMAN LAWRENCE Director | Grant or award · Stock Option (right to buy) | +7,500 | 7,500 | ||
| 2024-03-01 | STEINMAN LAWRENCE Director | Grant or award · Stock Option (right to buy) | +7,500 | 7,500 | ||
| 2024-03-01 | Schneiderman Daniel H Chief Financial Officer | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2024-03-01 | Schneiderman Daniel H Chief Financial Officer | Grant or award · Stock Option (right to buy) | +5,927 | 5,927 | ||
| 2024-03-01 | Novak Alfred J Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2024-03-01 | Marques Tiago Chief Executive Officer | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2024-03-01 | Marques Tiago Chief Executive Officer | Grant or award · Stock Option (right to buy) | +11,669 | 11,669 | ||
| 2024-03-01 | Leahy Emer Director | Grant or award · Stock Option (right to buy) | +7,500 | 7,500 | ||
| 2024-03-01 | Dumesnil Simon Director | Grant or award · Stock Option (right to buy) | +7,500 | 7,500 | ||
| 2024-03-01 | Currie Graeme Martin Chief Development Officer | Grant or award · Stock Option (right to buy) | +5,938 | 5,938 |
Page 2 of 4 · 79 trades